University of Pennsylvania researchers have found a way of traversing the blood-brain barrier, as well as a similar physiological obstacle in the eye, the retinal-blood barrier
The body is structured to ensure that any invading organisms have a tough time reaching the brain, an organ obviously critical to survival. Known as the blood-brain barrier, cells that line the brain and spinal cord are tightly packed, making it difficult for anything besides very small molecules to cross from the bloodstream into the central nervous system. While beneficial, this blockade also stands in the way of delivering drugs intended to treat neurological disorders, such as Alzheimer’s.
In a new study published in the journal Molecular Therapy, University of Pennsylvania researchers have found a way of traversing the blood-brain barrier, as well as a similar physiological obstacle in the eye, the retinal-blood barrier. By pairing a receptor that targets neurons with a molecule that degrades the main component of Alzheimer’s plaques, the biologists were able to substantially dissolve these plaques in mice brains and human brain tissue, offering a potential mechanism for treating the debilitating disease, as well as other conditions that involve either the brain or the eyes.
The work was led by Henry Daniell, a professor in Penn’s School of Dental Medicine’s departments of biochemistry and pathology and director of translational research. The research team included Penn Dental Medicine’s Neha Kohli, Donevan R. Westerveld, Alexandra C. Ayache and Sich L. Chan. Co-authors at the University of Florida College of Medicine, including Amrisha Verma, Pollob Shil, Tuhina Prasad, Ping Zhu and Quihong Li, analyzed retinal tissues.
The researchers began their work by considering how they might breach the blood-brain barrier. Daniell hypothesized that a molecule might be permitted to cross if it was attached to a carrier that is able to pass over, as a sort of molecular crossing guard. The protein cholera toxin B, or CTB, a non-toxic carrier currently approved for use in humans by the Food and Drug Administration, is used in this study to traverse the blood-brain barrier.
They next identified a protein that could clear the plaques that are found in the brains of Alzheimer’s patients. These plaques, which are believed to cause the dementia associated with the disease, are made up of tangles of amyloid beta (A?), a protein that is found in soluble form in healthy individuals. Noting that myelin basic protein (MBP) has been shown to degrade A? chains, the team decided to couple it with CTB to see if MBP would be permitted to cross.
“These tangles of beta amyloid are known to be the problem in Alzheimer’s,” says Daniell. “So our idea was to chop the protein back to their normal size so they wouldn’t form these tangles.”
To test this idea, the Penn-led team first exposed healthy mice to the CTB-MBP compound by feeding them capsules of freeze-dried leaves that had been genetically engineered to express the fused proteins, a method developed and perfected by Daniell over many years as a means of orally administering various drugs and vaccines. Adding a green-fluorescent protein to the CTB carrier, the researchers tracked the “glow” to see where the mice took up the protein. They found the glowing protein in both the brain and retina.
“When we found the glowing protein in the brain and the retina we were quite thrilled,” said Daniell. “If the protein could cross the barrier in healthy mice, we thought it was likely that it could cross in Alzheimer’s patients brains, because their barrier is somewhat impaired.”
When CTB was not part of the fused protein, they did not see this expression, suggesting that their carrier protein, the crossing guard, was an essential part of delivering their protein of interest.
To then see what MBP would do once it got to the brain, Daniell and colleagues exposed the CTB-MBP protein to the brains of mice bred to have an Alzheimer’s disease. They used a stain that binds to the brain plaques and found that exposure to the CTB-MBP compound resulted in reductions of staining up to 60 percent, indicating that the plaques were dissolving.
Gaining confidence that their compound was appropriately targeting the plaques, the researchers worked with the National Institutes of Health to obtain brain tissue from people who died of Alzheimer’s and performed the same type of staining. Their results showed a 47 percent decrease in staining in the inferior parietal cortex, a portion of the brain found to play an important role in the development of Alzheimer’s-associated dementia.
As a final step, the researchers fed the CTB-MBP-containing capsules to 15-month-old mice, the equivalent of 80 or more human years, bred to develop Alzheimer’s disease. After three months of feeding, the mice had reductions in A? plaques of up to 70 percent in the hippocampus and up to 40 percent in the cortex, whereas mice fed capsules that contained lettuce leaves without CTB-MBP added and mice that were not fed any capsules did not have any reduction in evidence of brain plaques.
Because Alzheimer’s patients have also been found to have plaques in their eyes, the researchers examined the eyes of the mice fed the protein. They found that, indeed, the Alzheimer’s-mice did have retinal plaques, but those fed the CBP-MBP compound had undetectable A? plaques in their retinae.
“Really no one knows whether the memory problems that people who have Alzheimer’s disease are due to the dementia or problems with their eyes,” Daniell said. “Here we show it may be both, and that we can dissolve the plaques through an oral route.”
The Latest on: Traversing the blood-brain barrier
- Nanobiotechnology-Based Strategies for Crossing the Blood–Brain Barrieron April 23, 2024 at 5:00 pm
No writing assistance was utilized in the production of this manuscript. The blood–brain barrier (BBB) is a significant obstacle to therapeutic delivery for CNS disorders. Among various ...
- Microplastics may spread from gut to brain, finds studyon April 22, 2024 at 7:45 pm
In a study published in Environmental Health Perspectives, researchers examined how consuming microplastics in amounts similar to those found in our environment affected mice. Microplastics, found in ...
- Breaching the barrieron April 22, 2024 at 9:20 am
The blood-brain barrier has confounded the development ... One way of circumventing the 06-kDa size limit for biologics traversing the BBB is to design smaller versions of proteins.
- Nanoparticles Deliver Drugs Directly Across the Blood-Brain Barrieron April 22, 2024 at 9:02 am
This process results in the formation of the protein/biomolecular corona. This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier; our research shows that these gold ...
- Researchers set new standards for nanoparticles, helping patients with MS, ALS, Parkinson's diseaseon April 19, 2024 at 9:31 am
Is it possible for nanoparticles to go through the digestive system and deliver medicine directly to the brain tissue? Researchers from Michigan State University say yes, and their latest findings are ...
- Nanoparticles may enable direct medicine delivery to brain in neurodegenerative disorderson April 18, 2024 at 5:00 pm
This forms the protein/biomolecular corona. “This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier,” Mahmoudi explained. “Our research shows that these gold ...
- 18 Foods You are Eating That Are Gradually Destroying Your Brainon April 9, 2024 at 9:09 am
This compound can traverse the blood-brain barrier, contributing to the formation of harmful plaques in the brain and potentially causing significant memory deterioration. Certain pesticides can ...
- News tagged with blood-brain barrieron April 8, 2024 at 5:00 pm
Columbia researchers have discovered a genetic variant that reduces the odds of developing Alzheimer's disease by up to 70% and may be protecting thousands of people in the United States from the ...
- Novel "Tissue-in-a-CUBE" model mimics blood-brain barrier for drug testingon February 28, 2024 at 9:20 am
The blood-brain barrier is a strict gatekeeper around the ... interactions is extremely challenging because drugs have to traverse different types of tissues before reaching the target area ...
- Researchers model blood-brain barrier using “Tissue-in-a-CUBE" systemon February 28, 2024 at 2:05 am
The blood-brain barrier is a strict gatekeeper around the ... interactions is extremely challenging because drugs have to traverse different types of tissues before reaching the target area ...
via Bing News
The Latest on: Blood-brain barrier
- I’m a nutritionist – here are the best foods to eat for a healthy brainon April 26, 2024 at 10:01 pm
New research indicates that diet can have a significant impact on brain health. Here's what to eat to keep your grey matter happy ...
- Regeneration Biomedical doses first patient in phase I trial of stem cell therapy to deliver directly to brain of Alzheimer’s disease patientson April 25, 2024 at 1:31 am
Newport Beach, California Thursday, April 25, 2024, 14:00 Hrs [IST] ...
- 8 of the most expensive drugs in biopharma: Unraveling the costliest medicationson April 25, 2024 at 1:29 am
Find out what the ten most expensive drugs in the world currently are, as several gene therapies top the list.
- Neurosciences Ph.D. Student Wins Grad SLAM Top Prizeon April 23, 2024 at 2:05 am
Dean Antony encourages Tritons to tune in and cheer for Garcia-Pak during the UC Grad SLAM Final Round, which will be livestreamed from the LinkedIn Headquarters in San Francisco on May 3 at 10:30 a.m ...
- Microplastics may spread from gut to brain, finds studyon April 22, 2024 at 7:45 pm
In a study published in Environmental Health Perspectives, researchers examined how consuming microplastics in amounts similar to those found in our environment affected mice. Microplastics, found in ...
- Nanoparticles Deliver Drugs Directly Across the Blood-Brain Barrieron April 22, 2024 at 9:02 am
This process results in the formation of the protein/biomolecular corona. This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier; our research shows that these gold ...
- Eisai, BioArctic to develop new drug for Alzheimer’s that can cross blood-brain barrieron April 22, 2024 at 6:41 am
Eisai and BioArctic — the companies behind the first Alzheimer’s drug proven to slow disease progression — are inking another research partnership in the disease, this time utilizing the Swedish ...
- Fibrin Immunotherapy’s Potential for Treating Traumatic Brain Injuryon April 22, 2024 at 1:05 am
Traumatic brain injuries come with an amplified risk for developing dementia, but a new therapeutic target and a potential immunotherapy have been identified.
- Study reveals novel therapeutic target for traumatic brain injuryon April 19, 2024 at 10:34 am
Health outcomes vary greatly among the approximately 1.5 million Americans who survive a traumatic brain injury each year. Not only can these injuries cause loss of coordination, depression, ...
- A new therapeutic target for traumatic brain injuryon April 19, 2024 at 9:39 am
For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely. Not only can these injuries lead to a loss of coordination, depression, impulsivity, ...
via Bing News